Comparisons of renal-related indicators, therapeutic strategies and outcomes
| Clinical characteristics | Mean±SD/Positive (%) | Nominal p value | |
| High 2019 criteria score (n=59) | Low 2019 criteria score (n=61) | ||
| Follow-up period, month | 34.21±17.16 | 31.54±17.25 | 0.400 |
| AKI | 31 (52.54%) | 19 (31.15%) | 0.018 |
| SCr | 123.60±71.02 | 100.51±85.68 | 0.001 |
| Alb | 25.64±5.41 | 26.60±6.83 | 0.502 |
| eGFR | 79.86±35.49 | 86.86±34.74 | 0.009 |
| uPCR | 4.33±2.87 | 3.97±3.91 | 0.107 |
| Induction treatment | |||
| Methylprednisolone pulse | 23 (38.98%) | 15 (24.59%) | 0.090 |
| Prednisone | 10 (16.95%) | 19 (31.15%) | 0.267 |
| Prednisone+MMF | 17 (30.51%) | 19 (31.15%) | |
| Prednisone+CTX | 18 (28.81%) | 13 (21.31%) | |
| Prednisone+FK506 | 13 (22.03%) | 8 (13.11%) | |
| Prednisone+MMF+FK506 | 1 (1.69%) | 2 (3.28%) | |
| Temporary dialysis | 9 (15.25%) | 2 (3.28%) | 0.028 |
| Maintenance treatment | |||
| Prednisone | 11 (18.64%) | 21 (34.43%) | 0.08 |
| Prednisone+MMF | 26 (44.07%) | 20 (32.79%) | |
| Prednisone+FK506 | 10 (16.95%) | 4 (6.56%) | |
| Prednisone+MMF+FK506 | 4 (6.68%) | 9 (14.75%) | |
| Others | 7 (11.86%) | 7 (11.48%) | |
| Treatment response | |||
| Renal CR | 35 (59.32%) | 42 (68.85%) | |
| Renal PR | 20 (33.90%) | 15 (24.59%) | 0.52 |
| No remission | 4 (6.78%) | 4 (6.56%) | |
| Long-term outcome | |||
| Flare | 10 (16.95%) | 4 (6.56%) | 0.093 |
| ERSD | 1 (1.69%) | 1 (1.64%) | 1.000 |
| Death | 2 (3.39%) | 1 (1.64%) | 0.616 |
P-values <0.05 were considered as significance and marked in bold.
AKI, acute kidney injury; Alb, albumin; CR, complete remission; CTX, cyclophosphamide; eGFR, estimated glomerular filtration rate; ERSD, end-stage renal disease; MMF, mycophenolate mofetil; PR, partial remission; SCr, serum creatinine; uPCR, urine protein creatinine ratio.